Hemab Therapeutics bags US$157m in Series C financing

Hemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round. The round was led by Sofinnova Partners, with significant participation from a large long-only global asset management company, a global sovereign wealth fund, and Avoro Capital Advisors. Existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital also participated. As part of the financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join the Hemab Board.

Advancing Treatments for Glanzmann Thrombasthenia and Factor VII Deficiency

The company plans to use the funds to accelerate and expand its pipeline programmes. Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder.

The financing follows the successful completion of Sutacimig’s Phase II study in GT. A registration study is planned for 2026, alongside the expansion into a Phase II study for Factor VII deficiency.

Sutacimig is a subcutaneously administered bispecific antibody. One arm binds and stabilises endogenous Factor VIIa, while the other binds to TLT-1 on activated platelets. This mechanism allows Factor VIIa to accumulate in the body and be recruited to activated platelets, facilitating haemostatic plug formation.

Sutacimig has received Fast Track and Orphan Drug Designations from the US FDA for GT. The UK Medicines and Healthcare products Regulatory Agency has granted it designation under the Innovative Licensing and Access Pathway (ILAP).

An international Glanzmann’s 360 (GT360) natural history study highlights the disease burden: 88% of 117 participants reported at least one bleed in the previous week, with 34% requiring medical treatment. These bleeding episodes affect mental health and quality of life: 67% reported low mood, 52% emotional problems, and 46% social isolation. Furthermore, 81% missed school or work due to bruising or bleeding. Currently, there are no effective prophylactic treatment options for GT.

Progress in Von Willebrand Disease treatment

The Series C financing will also support the advancement of HMB-002 towards a registration study. HMB-002 is an antibody-based treatment with Phase I data showing it can increase both Von Willebrand Factor (VWF) and Factor VIII levels.

HMB-002 is a monovalent human antibody being developed as the first-in-class prophylactic treatment targeting the root cause of Von Willebrand Disease (VWD), which is caused by a deficiency or defect in VWF, a key regulator of haemostasis. By targeting the C-terminal CK domain of VWF, HMB-002 protects the protein from degradation, increasing endogenous levels without affecting its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit.

VWD is the most common inherited bleeding disorder, characterised by quantitative or qualitative defects in VWF. It often leads to frequent mucocutaneous bleeding and heavy menstrual bleeding in women. Bleeding severity ranges from minor events to potentially life-threatening haemorrhages. Chronic blood loss frequently causes iron deficiency anaemia, worsening the disease burden and reducing quality of life. Current treatments mainly manage symptoms rather than addressing the underlying VWF defect.

Pipeline Expansion

The additional capital will allow Hemab to advance other novel drug candidates into clinical development. HMB-003 is expected to receive an IND in the first half of 2026.